Free Trial

Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Up 2.5% - Still a Buy?

Greenwich LifeSciences logo with Medical background

Key Points

  • Greenwich LifeSciences' stock price increased by 2.5% during mid-day trading, reaching a last traded price of $12.49, with trading volume decreasing by 48% compared to its average.
  • HC Wainwright has upgraded the company's price target from $38.00 to $39.00 while maintaining a "buy" rating on the stock.
  • The company's latest earnings report showed a loss of ($0.25) earnings per share, missing the consensus estimate by $0.01.
  • Want stock alerts on Greenwich LifeSciences? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) rose 2.5% during mid-day trading on Monday . The company traded as high as $12.70 and last traded at $12.49. Approximately 41,848 shares changed hands during trading, a decline of 48% from the average daily volume of 80,587 shares. The stock had previously closed at $12.18.

Analysts Set New Price Targets

Separately, HC Wainwright boosted their price objective on shares of Greenwich LifeSciences from $38.00 to $39.00 and gave the company a "buy" rating in a report on Monday, April 21st.

Get Our Latest Report on GLSI

Greenwich LifeSciences Stock Up 2.5%

The company has a market cap of $166.99 million, a price-to-earnings ratio of -9.91 and a beta of 1.65. The company's fifty day moving average price is $10.35 and its two-hundred day moving average price is $10.62.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last released its quarterly earnings results on Tuesday, May 20th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.01). On average, equities research analysts predict that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC acquired a new position in Greenwich LifeSciences during the first quarter worth $126,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Greenwich LifeSciences during the second quarter worth $25,000. Wells Fargo & Company MN raised its position in Greenwich LifeSciences by 54.8% during the fourth quarter. Wells Fargo & Company MN now owns 2,847 shares of the company's stock worth $32,000 after acquiring an additional 1,008 shares in the last quarter. JPMorgan Chase & Co. raised its position in Greenwich LifeSciences by 172.0% during the fourth quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company's stock worth $79,000 after acquiring an additional 4,465 shares in the last quarter. Finally, Bank of America Corp DE raised its position in Greenwich LifeSciences by 22.3% during the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock worth $82,000 after acquiring an additional 1,322 shares in the last quarter. Institutional investors and hedge funds own 4.16% of the company's stock.

Greenwich LifeSciences Company Profile

(Get Free Report)

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Greenwich LifeSciences Right Now?

Before you consider Greenwich LifeSciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Greenwich LifeSciences wasn't on the list.

While Greenwich LifeSciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines